Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Shaw

Showing results (661-670 of 742) with videos related to

Pageof 75
Sort By:
The Lancet. Oncology|December 29, 2015
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trialAlice T Shaw, Leena Gandhi, Shirish Gadgeel, et al.
Future Oncology (London, England)|June 12, 2023
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancerBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKAlice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, et al.
ESMO Open|December 7, 2017
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancerFiona Blackhall, D Ross Camidge, Alice T Shaw, et al.
Cancer Cell|April 20, 2004
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defectsDavid A Tuveson, Alice T Shaw, Nicholas A Willis, et al.
Lung Cancer (Amsterdam, Netherlands)|November 10, 2019
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancerSai-Hong Ignatius Ou, Shirish M Gadgeel, Fabrice Barlesi, et al.
Ebiomedicine|February 13, 2016
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung CancerRyohei Katayama, Takuya Sakashita, Noriko Yanagitani, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2017
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteriaLeena Gandhi, Sai-Hong Ignatius Ou, Alice T Shaw, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLCJessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX studyS Peters, R Camidge, R Dziadziuszko, et al.
Pageof 75

Showing results (661-670 of 742) with videos related to

Sort By:
Pageof 75
The Lancet. Oncology|December 29, 2015
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trialAlice T Shaw, Leena Gandhi, Shirish Gadgeel, et al.
Future Oncology (London, England)|June 12, 2023
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancerBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKAlice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, et al.
ESMO Open|December 7, 2017
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancerFiona Blackhall, D Ross Camidge, Alice T Shaw, et al.
Cancer Cell|April 20, 2004
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defectsDavid A Tuveson, Alice T Shaw, Nicholas A Willis, et al.
Lung Cancer (Amsterdam, Netherlands)|November 10, 2019
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancerSai-Hong Ignatius Ou, Shirish M Gadgeel, Fabrice Barlesi, et al.
Ebiomedicine|February 13, 2016
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung CancerRyohei Katayama, Takuya Sakashita, Noriko Yanagitani, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2017
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteriaLeena Gandhi, Sai-Hong Ignatius Ou, Alice T Shaw, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLCJessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX studyS Peters, R Camidge, R Dziadziuszko, et al.
Pageof 75